Brief: Ayala Pharmaceuticals Announces Continuation Of Ringside Phase 2/3 Study In Desmoid Tumors
03/03/2023 13:04
March 3 (Reuters) - Ayala Pharmaceuticals Inc ADXS.PK :
* AYALA PHARMACEUTICALS ANNOUNCES CONTINUATION OF RINGSIDE
PHASE
2/3 STUDY IN DESMOID TUMORS FOLLOWING RECOMMENDATION OF
INDEPENDENT DATA MONITORING COMMITTEE
* UPDATED DATA ON AL102 PHASE 2 SEGMENT OF RINGSIDE ARE
PLANNED
FOR PRESENTATION AT A MEDICAL MEETING IN 2023
Source text for Eikon: ID:nGNX7j9YDJ
Further company coverage: ADXS.PK
Recent news on Ayala Pharmaceuticals
See all newsBrief: Ayala Pharmaceuticals Completes Sale Of AL102 To Immunome
Immunome slides on $200 mln equity offering
Immunome edges up after $200 mln equity offering
Brief: Immunome To Acquire AL102 Phase 3 Asset for the Treatment of Desmoid Tumors From Ayala Pharmaceuticals
Brief: Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors